Background: Cardiac arrest (CA) is a significant cause of mortality in patients with heart failure (HF). Despite improvements in care, disparities in CA-related mortality among HF patients persist. This study seeks to explore demographic patterns and mortality rates. Methods: CDC WONDER (1999-2023) data was analyzed to assess CA-related mortality in HF patients aged≥25. Using the Joinpoint regression analysis, we calculated age-adjusted mortality rates (AAMR) per 100,000 patients and average annual percentage changes (AAPC) to analyze the mortality trends. Results: CA is responsible for a staggering 1,139,963 deaths among HF patients. The AAMRs have decreased from 25.3 in 1999 to 20.6 in 2023 (AAPC: -0.88, p-value < 0.01), the decline was most significant from 1999 to 2011 (APC: -2.95, p < 0.01) before a concerning rise from 2018 to 2021 (APC: 5.10, p-value < 0.01). Disparities are evident, with men facing higher AAMRs than women (24.6 vs. 17.6) and Black individuals at the highest risk (AAMR: 28.8) followed by Hispanics (AAMR: 22.8). Regionally, Mississippi reports the highest AAMR at 52.5, contrasting with Maryland's lowest rate of 4.3. Moreover, rural areas exhibited higher AAMRs than urban settings (20.9 vs. 20.1). Conclusion The rising mortality rates from CA in HF patients?especially among men, Black individuals, and those in rural areas?require our immediate attention. By implementing targeted interventions and enhancing access to healthcare, we can reduce these disparities and improve patient outcomes.

The authors have declared no competing interest.

None

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

N/A

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data was available in the manuscript and supplemental files.